G1 Therapeutics Inc - ESG Rating & Company Profile powered by AI
This analysis of G1 Therapeutics Inc was assembled by All Street Sevva using leading machine learning. If you work at G1 Therapeutics Inc and you would like to use your Sustainability rating, please contact us. Complete Sustainability assessment of G1 Therapeutics Inc can be accessed by signing up for free.
G1 Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.8; made up of an environmental score of 6.0, social score of 6.4 and governance score of 8.0.
6.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 294 | SMS Pharmaceuticals Ltd | 6.9 | High |
| 294 | Takeda Pharmaceutical Co Ltd | 6.9 | High |
| 314 | G1 Therapeutics Inc | 6.8 | High |
| 314 | Camurus AB | 6.8 | High |
| 314 | Cassiopea SpA | 6.8 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does G1 Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes G1 Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes G1 Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes G1 Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes G1 Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes G1 Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes G1 Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes G1 Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid G1 Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes G1 Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas G1 Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes G1 Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes G1 Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs G1 Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes G1 Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes G1 Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes G1 Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for G1 Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.